![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Locus Biosciences
Main focus: New treatments against bacterial infections
Company stage: Clinical
Diseases: Urinary tract infection, other infections
Genome editing tool: CRISPR-Cas3
Funding stage: Private
Location: North Carolina, USA
Website: https://www.locus-bio.com/
Partners: Janssen Pharma
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_LOCUS-bio-logo2_964a231c1c_8ada9cfb8b.png)
Locus Biosciences is a clinical-stage gene-editing company focused on treating bacterial infectious diseases. The company uses its next generation sequencing-based platform to rapidly identify new bacterial targets and phages. Locus uses CRISPR-Cas3 crPhages as the base of their therapies. The phages are designed using machine learning in order to optimise effectiveness against new bacterial targets.